Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities.
2 reports, 2 independent
Updated Jul 8
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Ultragenyx reports using GRI and SASB indices, and Emil Kakkis is named as CEO.1 source
- The Orbit study, involving Ultragenyx Pharmaceutical and ORBIT, is evaluating the drug UX143 for osteogenesis imperfecta.Sub-event
Ultragenyx leading Orbit study; Dr. Scots-Knight appointed CEO.1 source
Keep exploring
The entities involved
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireMereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around yea